Validation of the NEOS score in Chinese patients with anti-NMDAR encephalitis
Yujing Peng, Feifei Dai, Lei Liu, Weiqi Chen, Hongyi Yan, Aihua Liu, Xinghu Zhang, Xiaohui Wang, Junying He, Yatong Li, Chenxi Li, Liuxi Chen, Yan Zhao, Lin Li, Qiuying Ma, Jiawei Wang, Yujing Peng, Feifei Dai, Lei Liu, Weiqi Chen, Hongyi Yan, Aihua Liu, Xinghu Zhang, Xiaohui Wang, Junying He, Yatong Li, Chenxi Li, Liuxi Chen, Yan Zhao, Lin Li, Qiuying Ma, Jiawei Wang
Abstract
Objective: The performance of anti-NMDAR Encephalitis One-Year Functional Status (NEOS) in predicting the 1-year functional status in Chinese patients with anti-NMDAR encephalitis is unknown.
Methods: We recruited patients with anti-NMDAR encephalitis from the Multicenter and Prospective Clinical Registry Study of Anti-NMDAR Encephalitis in Beijing Area. Patients were followed up for 1 year. We defined the poor functional status as a modified Rankin Scale score of more than 2 and good functional status as a modified Rankin Scale score of no more than 2. We performed a receiver-operator characteristic analysis to assess the discriminatory power of the NEOS score in predicting the 1-year functional status by using the area under the curve (AUC). Calibration was assessed by Pearson correlation coefficient and Hosmer-Lemeshow tests.
Results: Among the 111 patients with anti-NMDAR encephalitis recruited from 364 potentially eligible participants, 87 (78.4%) had good functional status at 1 year, whereas the remaining 24 (21.6%) had poor functional status. The AUC of the NEOS score for 1-year poor functional status was 0.86 (95% CI 0.78-0.93, p < 0.001). The increased NEOS was associated with higher risk of 1-year poor functional status in patients with anti-NMDAR encephalitis.
Conclusions: The NEOS score is considered a reliable predictor of the risk of 1-year poor functional status in Chinese patients with anti-NMDAR encephalitis. This score could help to estimate the velocity of clinical improvement in advance.
Clinicaltrialgov identifier: NCT02443350.
Classification of evidence: This study provides Class III evidence that in patients with anti-NMDAR encephalitis, the NEOS score predicts 1-year functional status.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures
References
- Dalmau J, Graus F. Antibody-mediated encephalitis. N Eng J Med 2018;378:840–851.
- Dalmau J, Gleichman AJ, Hughes EG, et al. . Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–1098.
- Broadley J, Seneviratne U, Beech P, et al. . Prognosticating autoimmune encephalitis: a systematic review. J Autoimmun 2019;96:24–34.
- Titulaer MJ, McCracken L, Gabilondo I, et al. . Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–165.
- Titulaer MJ, McCracken L, Gabilondo I, et al. . Late-onset anti-NMDA receptor encephalitis. Neurology 2013;81:1058–1063.
- Irani SR, Stagg CJ, Schott JM, et al. . Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013;136:3151–3162.
- Graus F, Titulaer MJ, Balu R, et al. . A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391–404.
- Jaquet P, de Montmollin E, Dupuis C, et al. . Functional outcomes in adult patients with herpes simplex encephalitis admitted to the ICU: a multicenter cohort study. Intensive Care Med 2019;45:1103–1111.
- de Montmollin E, Demeret S, Brulé N, et al. . Anti-N-methyl-d-aspartate receptor encephalitis in adult patients requiring intensive care. Am J Respir Crit Care Med 2017;195:491–499.
- Pillai SC, Hacohen Y, Tantsis E, et al. . Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome. Pediatrics 2015;135:e974–e984.
- Balu R, McCracken L, Lancaster E, Graus F, Dalmau J, Titulaer MJ. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology 2019;92:e244–e252.
- Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63–74.
- Li L, Sun L, Du R, et al. . Application of the 2016 diagnostic approach for autoimmune encephalitis from Lancet Neurology to Chinese patients. BMC Neurol 2017;17:195.
- Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012;79:1094–1100.
- Vora NM, Holman RC, Mehal JM, Steiner CA, Blanton J, Sejvar J. Burden of encephalitis-associated hospitalizations in the United States, 1998–2010. Neurology 2014;82:443–451.
- Wang W, Li JM, Hu FY, et al. . Anti-NMDA receptor encephalitis: clinical characteristics, predictors of outcome and the knowledge gap in southwest China. Eur J Neurol 2016;23:621–629.
- Wang Y, Zhang W, Yin J, et al. . Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: clinical features, treatment, influencing factors, and outcomes. J Neuroimmunol 2017;312:59–65.
- Zhang Y, Liu G, Jiang M, Chen W, He Y, Su Y. Clinical characteristics and prognosis of severe anti-N-methyl-D-aspartate receptor encephalitis patients. Neurocrit Care 2018;29:264–272.
- Lim JA, Lee ST, Jung KH, et al. . Anti-N-methyl-d-aspartate receptor encephalitis in Korea: clinical features, treatment, and outcome. J Clin Neurol 2014;10:157–161.
- Irani SR, Bera K, Waters P, et al. . N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133:1655–1667.
- Florance NR, Davis RL, Lam C, et al. . Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11–18.
Source: PubMed